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O ral squamous cell carcinoma (OSCC) is one of the top 10 most common malignancies world-
wide [1].  Despite some progress in diagnostics and 
therapeutic options,  the 5-year overall survival rate for 
OSCC patients has stagnated at 40-50% over the last 40 
years [2-5].  The low survival rates in combination with 
the significant toxicities caused by the current treatment 
strategies used for OSCC emphasize the need for new 
treatment options.  In OSCC and other cancers,  the 
immune system plays an important role in the develop-
ment and progression,  and recent cancer immunother-
apies have focused on immunoregulatory molecules in 
the tumor microenvironment,  including immune 
checkpoints [6].
For example,  programmed cell death-1 (PD-1) is 
expressed in activated T and B cells.  Its major ligand 
(PD-L1) is expressed in antigen presenting cells,  as well 
as in tumor cells.  Aberrant PD-L1 expression in cancers 
facilitates an escape from immune attack [7 , 8].  
Nivolumab,  an anti-PD-1 therapeutic agent,  was 
recently approved by the U.S.  Food and Drug 
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Anticancer drugs induce cell-cycle arrest and apoptosis not only in tumor cells,  but also in immune cells.  
However,  many preclinical and clinical findings show that some chemotherapeutic agents can improve the anti-
tumor efficacy of immunotherapy.  We immunohistochemically analyzed the degree of immune cell infiltration 
and the relevance of programmed cell death 1 ligand-1 (PD-L1) expression in surgically resected oral squamous 
cell carcinoma (OSCC) specimens from patients who had undergone pretreatment with certain chemotherapies 
and other patients without pretreatment.  We divided the patients into the group of neoadjuvant chemotherapy 
(NAC) patients (n = 8) and the nNAC (without NAC) patient group (n = 10).  We observed that NAC induced 
infiltrations of CD4,  CD8 T cells and CD56 NK cells into the tumor microenvironment.  Decreased numbers of 
Tregs and PD-1-positive cells were observed in the NAC group.  No significant difference was observed in the 
degree of immune-cell infiltration between the patient groups except for CD56 NK cells in the stroma and PD-1 
cells in cancer nests.  Eighty percent of the nNAC specimens showed intermediate-to-strong PD-L1 protein 
expression,  whereas 75% of the NAC specimens showed down-regulation of the PD-L1 protein,  indicating the 
effectiveness of the chemotherapeutic treatment before surgery.
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Administration for the treatment of various malignan-
cies,  and it is currently being investigated in clinical 
phase III trials for the treatment of OSCC [9-12].
The tumor microenvironment is known to influence 
the curative and convalescent effects in patients who 
have undergone chemotherapeutic treatment,  due to the 
association between the tumor microenvironment and 
immune checkpoint inhibitors [13-19].  In the present 
study,  we retrospectively analyzed the degree of immune 
cell infiltration and the relevance of PD-L1 expression 
in surgically resected OSCC specimens from patients 
with or without pretreatment with certain chemothera-
pies.
Materials and Methods
OSCC patients. Eighteen patients were evaluated 
in this study.  Their characteristics are summarized in 
Table 1.  We retrospectively divided the patients into 2 
groups: the NAC group (n = 8) of patients who received 
neoadjuvant chemotherapy of FP (3 patients),  CDDP (1 
patient),  or S-1 (4 patients) followed by surgical resec-
tion; and the nNAC group (n = 10) of patients who 
underwent surgical resection without any neoadjuvant 
chemotherapy.  The median interval between the end of 
chemotherapy and the surgical resection for 8 patients 
in the NAC group was 19.6 days.  The mean age at diag-
nosis was 71 years (54-85 years) in the NAC group and 
65 years (32-81 years) in the nNAC group.  In the NAC 
group,  there were 3 stage II patients,  1 stage III patient,  
3 stage IVA patients,  and 1 stage IVB patient.  In the 
nNAC group,  there were 4 stage I patients,  2 stage II 
patients,  2 stage III patients,  and 2 stage IVA patients.
The white blood cell (WBC) counts before the surgi-
cal resection in each patient are also shown in Table 1.  
Cancer tissue specimens were obtained surgically from 
all of the patients at the Department of Maxillofacial 
Surgery at Okayama University Hospital between 2004 
and 2007.  Blood samples were also obtained from each 
patient.  Written informed consent for the analyses in 
the present study was obtained from all patients.  The 
study was conducted in accord with the Declaration of 
Helsinki regarding medical protocol and ethics.  The 
Ethics Committees of the Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences and Okayama University Hospital approved 
this study (Approval No. 1608-031).
Immunohistochemistry. The tumor specimens 
were fixed with buffered formalin and embedded in 
paraffin.  Sections (5 μm) were placed on glass slides,  
heated at 60°C for 20 min,  and then deparaffinized.  
The sections were treated by autoclaving for 5 min in 
0.01M citrate buffer (pH 6.0) for CD56,  HLA class I,  
CCDC62-2,  and MAGE-A antigen retrieval.
For CD4,  CD8,  FOXP3,  CCR4,  PD-1,  and PD-L1 
antigen retrieval,  slides in 0.01M citrate buffer (pH 9.0) 
were heated in a microwave for 5 min.  Endogenous 
peroxidase was then blocked by treatment with 0.3% 
H2O2 in methanol for 30 min at room temperature.  
After the blocking of endogenous peroxidase,  the sec-
tions were incubated overnight at 4°C with mouse 
monoclonal anti-CD4 antibody (1F6,  Leica Biosystems,  
Nussloch,  Germany),  mouse monoclonal anti-CD8 
antibody (C8/144B,  Dako,  Glostrup,  Denmark),  
mouse monoclonal anti-CD56 antibody (1B6,  Leica 
Biosystems),  mouse monoclonal anti-CCR4 antibody 
(POTELIGEO®TEST,  Kyowa Medex,  Tokyo,  Japan),  
mouse monoclonal anti-FOXP3 antibody (236A/E7,  
Abcam,  Cambridge,  UK),  mouse monoclonal 
anti-PD-1 antibody (NAT105,  Abcam),  mouse mono-
clonal anti-PD-L1 antibody (27A2,  MBL,  Nagoya,  
Japan),  mouse monoclonal anti HLA class I antibody 
(EMR8-5,  Hokudo,  Sapporo,  Japan),  mouse monoclo-
nal anti-MAGE-A antibody (6C1,  Thermo Fisher 
Scientific,  Waltham,  MA,  USA),  and mouse monoclo-
nal anti-CCDC62-2 antibody (mAb6212-1) [20 , 21].  A 
biotin-labeled secondary antibody was used for detect-
ing the primary antibody,  followed by an avidin-biotin 
complex system (ABC Elite,  Vector Laboratories,  
Burlingame,  CA).  Immunohistochemical reactions 
were visualized with 3,3-diaminobenzidine tetrahydro-
chloride.  Slides were counterstained with Mayer’s 
hematoxylin (Merck,  Darmstadt,  Germany).
Scoring of immune-related cell infiltration. The 
degree of immune cell infiltration was analyzed in more 
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Table 1　 Patient characteristics
nNAC (n＝10) NAC (n＝8)
Age (years) 65 (32-81) 71 (54-85) n.s.
Sex (male/female) 4/6 3/5 n.s.
Clinical Stage
I/II/III/IVA/IVB 4/2/2/2/0 0/3/1/3/1 n.s.
Preoperative WBC
(range) (×103/µL) 5.61 (3.0-9.3) 4.60 (2.7-6.9) n.s.
n.s.: no signiﬁcant.
than 10 independent high-power ( × 200) microscopic 
fields for each tissue sample.  The 5 areas of most abun-
dant distribution were selected.  The number of CD4 T 
cells,  CD8 T cells,  CD56 NK cells,  Treg cells,  and 
PD-1-positive cells were counted both in the tumor 
stoma and within the cancer nests.  Two investigators 
blinded to the patients’ clinical information evaluated 
all specimens.
Scoring of HLA class I and PD-L1 expression status.
The extent of immunohistochemical reactivity for HLA 
class I and PD-L1 was graded as follows: weak, < 25% 
cells stained; intermediate,  25-75% cells stained; and 
strong, > 75% cells stained.
Statistical analysis. We used the χ2 test to assess 
the significance of the associations between neoadju-
vant chemotherapy and clinicopathological parameters.  
The HLA class I and PD-L1 expression patterns between 
the NAC and nNAC groups were analyzed using the 
Mann-Whitney test.  We calculated disease-free survival 
(DFS) from the date of the operation to the date of the 
last follow-up or the date of the patient’s event.  
Differences in the DFS times between patient subgroups 
were analyzed using the log-rank statistic test.  We cal-
culated survival probabilities using the Kaplan-Meier 
method.  In all tests,  statistical significance was set at 
p < 0.05.
Results
Clinicopathological characteristics of the OSCC 
patients. The characteristics of the 18 patients eval-
uated in this study are summarized in Table 1.  We 
identified no significant differences in terms of preoper-
ative WBC count or lymphocyte count in peripheral 
blood between the 2 groups.  The Kaplan-Meier analysis 
found no association between the NAC and nNAC 
groups and the DFS (Fig. 1).
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Fig. 1　 Disease-free survival (DFS) curves in the NAC (n＝8) 







Fig. 2　 Representative immunohistochemical staining patterns of formalin-ﬁxed paraﬃn-embedded primary OSCC sections: (a) CD4,  (b) 
CD8,  (c) CD56,  (d) Treg (Foxp3),  (e) Treg (CCR4),  and (f) PD-1.  Scale bar,  100 µm.
Immunohistochemistry for immune-related cells.
We conducted an immunohistochemical analysis to 
determine the infiltration of immune-related cells such 
as CD4 T cells,  CD8 T cells,  CD56 NK cells,  Treg cells,  
and PD-1 positive cells in the cancer specimens.  A rep-
resentative immunohistochemical staining is shown in 
Fig. 2.  Fig. 3 shows the numbers of cells that infiltrated 
in the cancer nests and mesenchymal stroma.  A higher 
level of CD56 NK cells was found in the stroma than in 
the cancer nests.  Additionally,  in the stroma speci-
mens,  a significantly higher level of CD56-positive NK 
cells was found in the NAC group compared to the 
nNAC group.  No significant difference was observed in 
the other immune-related cells between the 2 groups.  
Although it was not significant,  a decreased number of 
PD-1-positive cells were found in the NAC group’s can-
cer nest specimens.  Thus,  we next investigated the 
expression patterns of PD-L1,  which is the major ligand 
of PD-1,  on the cancer cells in the specimens of the 
cancer nests.
PD-L1 expression. The examination of the PD-L1 
protein in the cancer nest specimens revealed that in the 
nNAC group,  80% (8/10) of the specimens showed 
intermediate-to-strong expression of PD-L1 protein 
whereas most of the NAC-group specimens (75%,  6/8) 
showed weak expression (Fig. 4).
HLA class I expression. Different expression pat-
terns of the HLA class I protein was observed between 
the 2 groups.  As shown in Fig. 5,  all 8 of the NAC 
specimens showed intermediate-to-strong expression.  
However,  10% (2/10) of the nNAC specimens showed 
weak expression,  suggesting a down-regulation of the 
HLA class I protein.
CT antigens’ expression. The expressions of CT 
antigens,  MAGE-A and CCDC62-2,  were evaluated.  
Staining was heterogeneous in the cancer nest and 
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Fig. 3　 The degree of immune-related cell inﬁltration in the tumor microenvironment of the NAC and nNAC groups.
localized in the cytoplasm (Fig. 6).  In the NAC group,  
positive staining was observed in 75% (6/8) of the spec-
imens for MAGE-A and 62.5% (5/8) of the specimens 
for CCDC62-2.  In the nNAC group,  positive staining 
was observed in 70% (7/10) of the specimens for 
CCDC62-2,  but only 30% (3/10) of the specimens for 
MAGE-A (Table 2).  Four specimens in the NAC group 
expressed both antigens (data not shown).
Discussion
Conventional chemotherapeutics are generally 
thought to kill cancer cells selectively.  Accumulating 
evidence indicates that several chemotherapeutic agents 
stimulate both the innate and adaptive immune systems 
[22].  Tsuchikawa et al.  showed that neoadjuvant che-
motherapy with 5-FU and cisplatin increased the intra-
tumoral infiltration of CD4 and CD8 T cells in patients 
with esophageal squamous cell carcinoma [23].  Nguyen 
et al.  demonstrated that multiple subsets of tumor-in-
filtrating lymphocytes were strong prognostic factors for 
previously untreated OSCC patients [24].  In the present 
study,  we showed that NAC induced the infiltration of 
CD4,  CD8 T cells and CD56 NK cells into the tumor 
microenvironment.  Conversely,  decreased numbers of 
Tregs and PD-1-positive cells were observed in the NAC 
group.  These findings indicate that conventional che-
motherapies may be beneficial in the development of 
immunotherapeutic protocols for OSCC patients.
Cancer-testis (CT) antigens elicit an immune 
response in cancer patients and are therefore targets of 
immunotherapy [20].  In the present study,  MAGE-A 
protein,  a prototype CT antigen,  was expressed in 3/10 
(30%) of the nNAC patients.  A high frequency of anti-
gen expression was observed in the NAC patients (6/8,  
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Fig. 4　 PD-L1 protein expression.  A,  Immunohistochemical staining patterns.  
(a) ʻWeakʼ: ＜25% of tumor cells were positively stained; (b) ʻIntermediateʼ:  
25-75%; (c) ʻStrongʼ: ＞75%.  Scale bar,  200 µm; B,  PD-L1 expression 
intensity and frequency of the NAC and nNAC groups.

























Fig. 6　 Immunohistochemical staining of MAGE-A and CCDC62-2 antigens.  a, d: Strong staining.  b, e: Weak staining.  c, f: Negative.  
Scale bar,  200 µm.
Fig. 5　 HLA class I protein expression.  A,  Immunohistochemical staining 
patterns.  (a) ʻWeakʼ: ＜25% of tumor cells were positively stained; (b) 
ʻIntermediateʼ: 25-75%; (c) ʻStrongʼ: ＞75%.  Scale bar,  200 µm; B,  HLA 
protein staining intensity and frequency of the NAC and nNAC groups.
75%),  indicating that NAC patients would be eligible for 
immunotherapeutic treatment.
Immune checkpoints that maintain physiologic 
self-tolerance were implicated in the down-regulation of 
anti-tumor immunity [10].  PD-1,  a cell surface recep-
tor that is a member of the CD28 family of T-cell regu-
lators,  is found on activated T and B lymphocytes as 
well as NK cells in the microenvironment.  Its binding to 
the ligand PD-L1 on tumor cells causes a down-regula-
tion of T-cell activation,  leading to reduced prolifera-
tion and to the expression of anti-apoptotic molecules 
and production of cytokines [25].  PD-L1 expression 
has been identified in tumor cells of different types of 
cancer,  including OSCC,  and is correlated with the 
tumor grade or prognosis in several types of carcinomas 
[26].  Blocking the interaction between PD-1 and 
PD-L1 using monoclonal antibodies has been reported 
to be a successful treatment for patients with several 
types of cancer,  including melanoma,  lung cancer,  and 
kidney cancer [7].  A frequent expression of PD-L1 was 
observed in OSCCs compared with other cancers [27].
Our immunohistochemical analysis of the infiltra-
tion of immune-related cells and PD-1 and PD-L1 pro-
tein expression in the surgically resected specimens 
from OSCC patients with NAC and without presurgical 
treatment revealed no distinct between-group difference 
in the degree of immune-cell infiltration,  but a 
decreased number of PD-1-positive cells were observed 
in the NAC cancer nest specimens.  In fact,  75% of the 
NAC group showed weak PD-L1 protein expression,  
unlike the nNAC group’s intermediate-to-strong PD-L1 
protein expression in 80% of the specimens.
The expression of PD-L1 is significantly associated 
with the histopathological grade in some tumors,  
including infiltrating ductal carcinoma [28] and urothe-
lial carcinoma [29].  However,  the overall prognosis 
value of the PD-L1 status is controversial.  PD-L1 
expression is considered a poor-prognosis factor in can-
cers such as non-small cell lung cancer,  renal cell carci-
noma,  and melanoma [30-32].  In contrast,  PD-L1 
expression is a good-prognosis factor in colorectal can-
cer [33].  A recent study revealed that a subset of OSCC 
patients who were male or had a smoking habit and 
exhibited high levels of PD-L1 expression has poor clin-
ical outcomes [34].  A smoking history was also mar-
ginally associated with PD-L1 expression in non-small 
cell lung cancer [35].  In our present study,  no associa-
tion was found between the groups of NAC (weak 
PD-L1 expression) and nNAC (intermediate-to-strong 
PD-L1 expression) patients and the disease-free sur-
vival.
A limitation of our study is the small number of 
cases.  More detailed studies of larger numbers of 
patients with a variety of clinical-pathological features 
are needed to address the statistically reliable evidence 
of immune responses within the tumor microenviron-
ment.  In conclusion,  our observation revealed that 
most of the NAC specimens showed down-regulation of 
the PD-L1 protein,  indicating the effectiveness of che-
motherapeutic treatment before surgery for OSCC.
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